Vidutolimod is under clinical development by Regeneron Pharmaceuticals and currently in the Phase I, Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Vidutolimod’s likelihood of approval (LoA) and phase transition for Triple-Negative Breast Cancer (TNBC) took place on 06 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Vidutolimod Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Vidutolimod overview

CMP-001 (CYT-003) is under development for the treatment of recurrent or metastatic head and neck squamous cell carcinoma, head and neck cancer, hepatocellular carcinoma, merkel cell carcinoma, relapsed and refractory B and T cell Hodgkin lymphoma or Non-Hodgkin lymphoma, Oropharyngeal Cancer, oral cavity, hypopharynx, or larynx cancer, metastatic colorectal cancer, cutaneous squamous cell carcinoma (CSCC), advanced cutaneous melanoma, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), triple-negative breast cancer (TNBC), gastric cancer, platinum resistant ovarian cancer, bladder cancer, small cell lung cancer (SCLC), metastatic castration resistant prostate cancer and progressing tenosynovial giant cell tumor/pigmented villonodular synovitis (TGCT/PVNS). The drug candidate is administered through subcutaneous and intratumoral route. It consists of QbG10 with virus-like particle Qb filled with a synthetic immunostimulatory DNA sequence called G10. It acts by targeting Toll-like receptor 9. It was also under development for the treatment of allergic asthma, allergic rhinitis, allergic rhinoconjunctivitis, HBV infections and atopic dermatitis.

Regeneron Pharmaceuticals overview

Regeneron Pharmaceuticals (Regeneron) is engaged in discovering, developing, manufacturing, and marketing medicines for the treatment of serious medical conditions. Its products are focused on helping patients suffering from cancer, allergic and inflammatory diseases, eye diseases, metabolic and cardiovascular diseases, infectious diseases, neuromuscular diseases, and rare diseases. It develops products using its Trap and VelociSuite technology platforms, which include VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, and other related technologies. The company operates manufacturing facilities in Rensselaer, New York, and Limerick, Ireland. It also collaborates with strategic partners to develop, manufacture, and commercialize its products. It sells its products to specialty pharmacies and distributors. The company operates in the US, the Netherlands, Bermuda, Ireland, Spain, and the UK. Regeneron is headquartered in Tarrytown, New York, the US.

Quick View Vidutolimod LOA Data

Report Segments
  • Innovator
Drug Name
  • Vidutolimod
Administration Pathway
  • Intratumor
  • Subcutaneous
Therapeutic Areas
  • Dermatology
  • Infectious Disease
  • Musculoskeletal Disorders
  • Oncology
  • Ophthalmology
  • Respiratory
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.